| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Biote Corp. Class A Common Stock$2.26
-0.15 (-6.6%)
Market Cap
68.55 M
EPS
0.86
P/E Ratio
2.62 $
Value Trade
405.62 K
SEC Financials
Q1 2026Dilution Risk
Revenue
44.94 M
Operating CF
3.90 M
Total Assets
89.03 M
Total Liabilities
136.99 M
Equity
-56.09 M
10.78 %
Week
-0.88 %
1 Month
2.73 %
3 Month
1.8 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
5.32 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
81.36 K
52 Week Range
1.27 - 3.62
% held by Insiders
9.39 %
% held by Institutions
65.37 %
Enterprise Value
171.04 M
Total Shares
30.32 M
Short %
2.11 %
Float Shares
22.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biote Corp. Class A Common Stock
88Total events
2Upcoming
9Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Patent Granted
Subscribe to view catalyst details
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Product LaunchUltratrutidePost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BTMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BTMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BTMD
Aug 5, 2026▼ -6.6%today
Biote Reports Second Quarter 2026 Financial Results
Biote, a leader in hormone optimization, announced its financial results for Q2 2026. The company highlighted significant progress in its strategic initiatives, which are expected to lead to sustainable revenue growth. CEO Bob Peterso emphasized the improvements made over the past year, reflecting a positive outlook for the company's future.
Read more →-BTMD
Jul 27, 2026Biotech Innovator InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform
InstaMed® Pharmaceuticals has appointed Tracy Gibbs, PhD, as CEO to spearhead the launch of its innovative non-injectable peptide delivery platform. The company is set to introduce five new oral dissolving peptide products on August 3, 2026, following successful pharmacokinetic study results. This advancement aims to enhance patient access to peptide therapies while addressing the limitations of traditional injections.
Read more →-BTMD
Jul 22, 2026Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
Biote Corp. has announced that it will release its second quarter financial results on August 5, 2026, after market close. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss the results. This event highlights the company's commitment to keeping stakeholders informed.
Read more →-BTMD
Jul 14, 2026Biotech Visionary John F. Crowley to Keynote Emily Whitehead Foundation's 2026 Believe Ball in Philadelphia
The Emily Whitehead Foundation will host its 2026 Believe Ball in Philadelphia, featuring John F. Crowley as the keynote speaker. The event aims to bridge the gap between patients and industry leaders in advanced therapies, particularly CAR T-cell therapy. It serves as a fundraiser to support patients affected by cancer and rare diseases, celebrating stories of hope and innovation.
Read more →-BTMD
Jul 1, 2026▲ +5.3%on this news· ran to +19% by day 3
Biotech Startup Turns to Space to Manufacture Artificial Retinas for Treating Blindness
LambdaVision, a biotech startup, is utilizing microgravity on the ISS to manufacture artificial retinas aimed at restoring vision for those with macular degeneration. The unique environment allows for improved material properties and production efficiency. The company plans to continue its research and production in future commercial space stations after the ISS retirement.
Read more →-BTMD
Jun 22, 2026BIOTECanada Opens Canada Pavilion at BIO 2026 Amid Major Policy Momentum for Canadian Biotech
BIOTECanada has announced the opening of the Canada Pavilion at BIO 2026. This initiative comes at a time when there is significant policy momentum supporting the Canadian biotech sector. The pavilion aims to showcase Canadian innovations and foster international collaborations within the industry.
Read more →-BTMD
Jun 22, 2026BIOTECanada inaugure le Pavillon du Canada à BIO 2026, dans un contexte de grande dynamique politique en faveur de la biotechnologie canadienne
BIOTECanada has inaugurated the Canada Pavilion at BIO 2026, highlighting the political momentum supporting Canadian biotechnology. This event is part of a broader initiative to showcase Canada's advancements and contributions to the biotech sector. The pavilion aims to foster collaboration and innovation within the industry.
Read more →-BTMD
Jun 1, 2026▲ +5.5%on this news· ran to +18% by day 3
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
Biote has announced the appointment of Komal Bajaj, MD, MS as its new Chief Medical Officer. This leadership change is part of the company's strategy to enhance its medical expertise. Dr. Bajaj brings significant experience in the biopharma sector to her new role.
Read more →-BTMD
May 28, 2026Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
Biote has appointed Bob Peterson, the current Chief Financial and Chief Business Officer, as the Interim CEO. This leadership change comes as the company seeks to navigate its strategic direction. Further details regarding the transition and its implications for the company have not been disclosed.
Read more →-BTMD
May 6, 2026Biote Reports First Quarter 2026 Financial Results
Biote has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance during this period. Specific details regarding revenue, expenses, and other financial metrics were not disclosed in the text provided.
Read more →-BTMD
Apr 22, 2026Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
Biote has announced the scheduling of its financial results release for the first quarter of 2026, along with a conference call to discuss these results. This event aims to provide stakeholders with insights into the company's financial performance and future outlook. Further details regarding the call will be shared closer to the date.
Read more →-BTMD
Apr 3, 2026Transforming Healthy Aging 2 Transforming Healthy Aging Forward-Looking Statements Forward-Looking Statements Certain statements in this Presentation may be considered "forward-looking statements" within the meaning of t
Biote Holdings presented forward-looking statements regarding its financial performance and growth strategy. The projections include a revenue estimate of $192.2 million for 2025 and highlight the expertise of over 9,200 Biote-certified practitioners. However, the company acknowledges multiple risks, including reliance on third-party partners and the competitive landscape, which may affect its business operations. These statements are based on certain assumptions and are not guarantees of future results.
Read more →-BTMD
Mar 11, 2026Biote Reports Fourth Quarter and Full Year 2025 Financial Results Executing efficiently on strategic priorities Continued salesforce expansion to capture large growth opportunity Anticipate a return to procedure revenue
Biote (NASDAQ: BTMD) has reported its fourth quarter and full year 2025 financial results, revealing a revenue of $46.4 million for the last quarter, which is a 6.9% decline year-over-year. The company highlights continued expansion in dietary supplements revenue and a projected return to procedure revenue growth in the latter half of 2026. Despite facing a decrease in procedure revenue by 13.0%, Biote's management remains optimistic about future investments in sales and technology capabilities. The strategic focus aims to enhance patient health and drive sustainable growth moving forward.
Read more →-BTMD
Feb 26, 2026Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
Biote Corp. has announced the release date for its fourth quarter and full year financial results, scheduled for March 11, 2026. A conference call will follow at 5:00 p.m. ET to discuss these results. The company emphasizes its commitment to hormone replacement therapy and healthy aging solutions, showcasing its innovative approach in the healthcare sector.
Read more →-BTMD
Nov 5, 2025Biote Reports Third Quarter 2025 Financial Results Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 202
Biote Corp. reported its financial results for the third quarter of 2025, noting a revenue of $48.0 million, a 6.7% decrease from the previous year. Despite challenges, the company highlighted an improved gross profit margin of 71.8% and successfully repurchased approximately one million shares. Net income declined to $9.2 million, reflecting lower sales and higher operating expenses. The company reiterated its financial guidance for 2025, expecting revenue to exceed $190 million and adjusted EBITDA to surpass $50 million.
Read more →-BTMD
Aug 6, 2025▼ -7.4%on this news· ran to -32% by day 3
Biote Reports Second Quarter 2025 Financial Results Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure gro
Biote reported its financial results for Q2 2025, marking a revenue of $48.9 million, slightly decreasing from $49.2 million a year prior. The company highlighted strong growth in dietary supplement sales, leading to an improved gross profit margin of 71.6%. Notably, Biote's organizational restructuring aims to drive sustainable growth, although procedure revenue has decreased by 8.4%. The company adjusted its 2025 revenue guidance to a range above $190 million, reflecting current market challenges and proactive changes in strategy.
Read more →-BTMD
Jun 9, 2025Biote Names Rich Barrera to Board of Directors IRVING, TX
Biote Corp. has appointed Rich Barrera to its Board of Directors, effective immediately. Barrera, the founder and CEO of Roystone Capital, has extensive experience in investment management and is recognized for his significant background in finance. His alignment with Biote's growth strategy is seen as beneficial as the company continues to expand its personalized hormone optimization and wellness solutions. This decision comes as Biote aims to enhance its market position in the preventive healthcare industry.
Read more →-BTMD
May 7, 2025Biote Reports First Quarter 2025 Financial Results Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and bu
Biote Corp. reported its financial results for Q1 2025, showcasing strong revenue growth of 4.7% year-over-year, primarily driven by a significant increase in dietary supplements revenue. Despite a slight decrease in procedure revenue, the company’s gross profit margin rose to 74.3% due to effective cost management and vertical integration. To support ongoing growth and operational efficiency, Biote announced an organizational restructuring aiming to enhance sales productivity and maximize value from existing providers. The company remains confident in meeting its financial guidance for the year.
Read more →-BTMD
Mar 12, 2025Biote Reports Fourth Quarter and Full Year 2024 Financial Results Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook IRVING, TX
Biote (BTMD) announced its fourth quarter and full year 2024 financial results, showcasing a 6.4% increase in revenue compared to 2023, supported by the rollout of its BioteRx platform and upgraded decision support software. Despite a slight increase in fourth quarter revenue by 9%, procedure volume was affected due to software transitions, impacting operating income. The company anticipates a slight increase in first quarter 2025 revenue due to enhanced practitioner training, coupled with a cautious outlook on future revenue growth due to necessary adjustments in their commercial strategy.
Read more →-BTMD
Jan 30, 2025Biote Announces CEO Retirement and Succession Plan Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company s Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Web
Biote Corp. announced the retirement of CEO Terry Weber, effective February 1, 2025, after six years of leading the company. Weber will transition to a Strategic Advisor role, and Bret Christensen has been appointed as her successor as CEO and Director. Under Weber's tenure, Biote became a prominent provider in hormone optimization, training over 7,000 practitioners. Christensen's extensive experience in women's health and related fields is anticipated to drive further innovation and growth for the company.
Read more →-BTMD
Nov 12, 2024Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitiv
Biote reported a 12.8% increase in revenue for Q3 2024, highlighting strong growth in both procedure revenue and dietary supplements. The company improved its gross profit margin to 70.5% through effective cost management and vertical integration. Despite achieving adjusted EBITDA growth of 15.4%, Biote faced temporary disruptions in procedure volume related to the launch of new software and hurricane-related clinic closures. Looking ahead, the company has adjusted its financial guidance for 2024, anticipating some continued impacts from these disruptions into the fourth quarter.
Read more →-BTMD
Aug 8, 2024Biote Reports Second Quarter 2024 Financial Results Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance IRVING, TX
Biote (NASDAQ: BTMD) reported its second quarter financial results for 2024, showcasing a sequential procedure revenue growth of 7.8% driven by strong demand from practitioners. Despite a net loss of $10.5 million, the company increased its investments in marketing and is on track with the roll-out of BioteRx, which has received positive responses. Management has reiterated its guidance for 2024, anticipating further growth due to an expanding clinic network and optimized onboarding processes. However, dietary supplement revenue has seen a significant decline as the company transitions its e-commerce operations.
Read more →-BTMD
Jun 20, 2024Biote Announces $60 Million Agreement to Repurchase 8.3 Million Shares and Cancel Approximately 4.0 Million Earnout Shares IRVING, TX
Biote Corp. has announced a $60 million agreement to repurchase 8.3 million shares owned by stockholder Marci M. Donovitz and cancel approximately 4.0 million earnout shares. This settlement is intended to resolve ongoing litigation and follows Biote's broader strategy to enhance shareholder value. The company will implement the share repurchase at an average price of $7.23 per share over a three-year period. Biote aims to continue focusing on profitable growth and establishing itself as a leader in personalized hormone optimization and wellness solutions.
Read more →-BTMD
May 7, 2024Biote Reports First Quarter 2024 Financial Results Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, wi
Biote (NASDAQ: BTMD) reported its financial results for the first quarter of 2024, showcasing a 6.6% increase in procedure revenue and reduced net loss. The phased launch of BioteRx is on track, with positive reception from patients and practitioners. While the total revenue rose to $46.8 million, a notable decline in dietary supplement revenue has been observed. The company reaffirmed its financial guidance for 2024, expecting stronger growth in the second half of the year.
Read more →-BTMD
Apr 29, 2024Biote Announces Definitive Settlement with Founder Company to repurchase all of Founder s 18.4 million shares at $4.17 per share IRVING, TX
Biote Corp. has reached a definitive settlement agreement with founder Dr. Gary S. Donovitz, resolving ongoing litigation. As part of the agreement, Biote will repurchase all 18.4 million shares held by Donovitz for approximately $76.9 million. The settlement includes mutual releases of claims and non-compete clauses. CEO Terry Weber expressed confidence that this decision will enhance shareholder value and allow the company to focus on strategic growth objectives.
Read more →-BTMD
Mar 12, 2024Biote Reports Fourth Quarter and Full Year 2023 Financial Results Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder valu
Biote (NASDAQ: BTMD) reported its financial results for the fourth quarter and full year of 2023, highlighting growth in procedure revenue and an expanded practitioner network. The company launched its BioteRx product line aimed at hormone optimization and preventive wellness, receiving positive provider feedback. A settlement with the founder to repurchase shares is expected to enhance shareholder value. Despite the revenue increase, dietary supplement sales declined and operating income fell due to rising costs.
Read more →-BTMD
Feb 20, 2024Biote Announces Agreement to Resolve Litigation and Repurchase All of Founder s Shares Company to repurchase approximately 18.4 million Class A shares and Paired Interests at $4.17 per share IRVING, TX
Biote Corp. has reached an agreement with founder Dr. Gary S. Donovitz to resolve ongoing litigation and repurchase approximately 18.4 million shares at $4.17 each. This settlement, totaling around $76.9 million, will include a mutual release of claims and new non-compete agreements for Donovitz. Biote's CEO stated that this move not only addresses costly litigation but also supports the company's goal of enhancing shareholder value and advancing its strategic objectives in therapeutic wellness.
Read more →-BTMD
Jan 25, 2024Biote Announces $20 Million Share Repurchase Authorization IRVING, TX
Biote Corp. has announced a $20 million share repurchase program, approved by its Board of Directors. This marks the company's first authorization for share repurchases, emphasizing its belief in strong growth potential despite market challenges. The program will allow management to buy back shares at their discretion, subject to various market conditions and regulations. CEO Terry Weber expressed confidence in the company's strategic direction and balance sheet, making this a pivotal moment for the firm.
Read more →-BTMD
Jan 17, 2024Biote Provides Preliminary 2023 Results and Initial 2024 Guidance IRVING, TX
Biote Corp. announced preliminary results for 2023, reporting expected revenue and Adjusted EBITDA slightly below prior guidance, with projected revenues of $185-$187 million. Despite challenges in 2023, including a decline in dietary supplement revenue due to a distributor exit, Biote anticipates a rebound with initial guidance for 2024 forecasting revenue above $200 million. The company plans to launch new therapeutic wellness products starting in the first quarter of 2024. Management remains optimistic about future growth driven by an increase in certified providers and improved product distribution.
Read more →-BTMD
Jan 11, 2024Biote Names Robert Peterson as Chief Financial Officer IRVING, TX
Biote Corp. has appointed Robert Peterson as its Chief Financial Officer, effective January 8, 2024. Peterson, who succeeds Samar Kamdar, comes with 15 years of experience in the health and wellness industry, including executive roles at Virbac Corporation and Alcon Laboratories. His transition is said to be unrelated to the company's financial results. Under Peterson's leadership, Biote aims to enhance its financial operations and capitalize on opportunities in the therapeutic wellness market.
Read more →-BTMD
Nov 7, 2023Biote Reports Third Quarter 2023 Financial Results Achieves Progress in Test of Complementary Wellness Therapeutics Reiterates 2023 Financial Guidance IRVING, TX
Biote reported its financial results for the third quarter of 2023, showcasing revenue growth of 8.5% compared to the same period last year, driven by increased patient demand for hormone optimization and wellness therapies. The company also achieved an adjusted EBITDA of $14.0 million, reflecting an improved margin of 30.8%. Management expressed satisfaction with the progress in their trials for complementary wellness therapeutics and reiterated their financial guidance for 2023, anticipating results to be at the lower end of their revenue and adjusted EBITDA targets. Overall, Biote remains focused on expanding their offerings and driving profitable growth.
Read more →-BTMD
Aug 10, 2023Biote Reports Second Quarter 2023 Financial Results Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Well
Biote (NASDAQ: BTMD) reported its financial results for the second quarter of 2023, demonstrating a solid revenue growth of more than 19% year-over-year. The company's Adjusted EBITDA margin stood at 29.5%, even amidst investments to enhance its capabilities. Biote launched a new Men's Health division, indicating its commitment to expanding its product offerings in the therapeutic wellness market. However, the company anticipates a more moderate growth pace in the latter half of 2023 due to temporary operational inefficiencies.
Read more →-BTMD
Jun 8, 2023Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX
Biote has announced the successful expiration of its exchange offer for warrants, with a notable 97.5% of public warrants and 87.4% of private placement warrants validly tendered. Furthermore, the company has obtained the necessary consent to amend the Warrant Agreement, enabling it to proceed with an exchange for shares of Common Stock. The SEC also declared Biote's Registration Statement effective, allowing for the issuance of these shares. This signifies a strategic move that could enhance shareholder value and streamline financial structure.
Read more →-BTMD
May 9, 2023▼ -7.2%on this news· ran to -17% by day 1
Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men s Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance IR
Biote (NASDAQ: BTMD) reported its first-quarter 2023 financial results, revealing a 21% year-over-year revenue growth but a net loss of $21.4 million compared to a net income of $9.4 million in the previous year. The company has launched a new initiative aimed at expanding into the men's health market, addressing a significant unmet need for testosterone treatment in over 20 million men over age 45. Biote is maintaining its 2023 financial guidance, anticipating ongoing revenue and Adjusted EBITDA growth throughout the year, despite a decrease in operating income due to increased expenses.
Read more →-BTMD
Mar 28, 2023Biote Reports Fourth Quarter and Full Year 2022 Financial Results Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 millio
Biote has reported its financial results for the fourth quarter and full year 2022, achieving record revenue of $165 million and adjusted EBITDA of $50.1 million. The company anticipates continued growth in 2023, projecting revenue between $190-200 million and adjusted EBITDA of $56-60 million, buoyed by the expansion of their sales team. However, the firm's operating loss was impacted by significant transaction-related costs and stock compensation expenses, highlighting some financial challenges despite the overall positive outlook.
Read more →-BTMD
Nov 8, 2022Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX
Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX November 8, 2022 - Biote (NASDAQ: BTMD), a leading provider of preventive heal
Read more →-BTMD
Nov 7, 2022▼ -7.3%on this newsshared move
Biote Appoints Debby Morris to Board of Directors IRVING, TX
Biote Appoints Debby Morris to Board of Directors IRVING, TX November 7, 2022 biote Corp. (Nasdaq: BTMD) ( Biote or the Company ), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris
Read more →-BTMD
Oct 10, 2022Biote Releases Updated Corporate Presentation for October 2022
Biote Releases Updated Corporate Presentation for October 2022 IRVING, Texas (BUSINESS WIRE) Oct. 10, 2022 biote Corp. (Nasdaq: BTMD) ( Biote or the Company ), a high growth, differentiated medical practice-building business within the hormone optimization space, today released
Read more →-BTMD
Aug 25, 2022Biote Announces Approval to Relist on The Nasdaq Stock Market Company will resume trading under its existing symbols BTMD and
Biote Announces Approval to Relist on The Nasdaq Stock Market Company will resume trading under its existing symbols BTMD and BTMDW IRVING, TX, August 25, 2022 biote Corp. ( Biote or the Company ), a high growth, differentiated medical practice-building business within the hor
Read more →-BTMD
Aug 24, 2022▲ +14.6%on this newsshared move
Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX
Biote Appoints Samar Kamdar as Chief Financial Officer IRVING, TX, August 24, 2022 biote Corp. ( Biote or the Company ), a high growth, differentiated medical practice-building business within the hormone optimization space, today announced that it has appointed Samar Kamdar as
Read more →-BTMD
Aug 15, 2022Biote Issues Correction to Second Quarter Operating Loss and Net Income IRVING, TX
Biote Issues Correction to Second Quarter Operating Loss and Net Income IRVING, TX, August 15, 2022 Biote today issued a correction to operating loss and net income for the three and six month periods ended June 30, 2022 in the press release titled Biote Reports Second Quarter
Read more →-BTMD
Aug 9, 2022Biote Reports Second Quarter 2022 Financial Results Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance *Revised Dial-in Information for the Conference C
Second Quarter 2022 Financial Results Company generates accelerated Revenue, net income and adjusted EBITDA growth, and raises 2022 adjusted EBITDA guidance *Revised Dial-in Information for the Conference Call* IRVING, TX, August 9, 2022 Biote, a high growth, differentiated m
Read more →-BTMD
Jun 9, 2022BioTE Holdings, LLC Unaudited Quarterly Financial Results for 2021 biote Corp. (the Company ) is furnishing the following tables which set forth supplemental unaudited financial information of BioTE Holdings, LLC and its
Unaudited Quarterly Financial Results for 2021 biote Corp. (the Company ) is furnishing the following tables which set forth supplemental unaudited financial information of BioTE Holdings, LLC and its subsidiaries ( Biote ) for the periods and as of the dates indicated. This su
Read more →-BTMD
Jun 2, 2022BIOTE HOLDINGS, LLC CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Quarterly Period ended
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Quarterly Period ended March 31, 2022 and 2021 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Quarterly Period Ended March 31, 2022 and 2021 Condensed Consolidated Financial Statements (Unaudited): Condensed Consolidated Balance Sh
Read more →-BTMD
May 26, 2022Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry Business combination with Haymaker Acquisition Corp. III complete biote Corp. s common stock will trade on the Nasdaq Stock Ex
Biote Debuts as Publicly Traded Company Focused on Transforming Hormone Optimization Industry Business combination with Haymaker Acquisition Corp. III complete biote Corp. s common stock will trade on the Nasdaq Stock Exchange under ticker symbol BTMD IRVING, TX, May 26, 2022
Read more →-BTMD
May 24, 2022Haymaker Acquisition Corp. III Announces Stockholder Approval of Business Combination with Biote
Haymaker Acquisition Corp. III Announces Stockholder Approval of Business Combination with Biote NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) Haymaker Acquisition Corp. III (Nasdaq: HYAC) ( Haymaker or the Company ), a publicly traded special purpose acquisition company, today annou
Read more →-BTMD
May 11, 2022Biote Reports First Quarter 2022 Financial Results and Provides Corporate Update Company accelerates expansion and reiterates 2022 guidance Net sales of $37 million in the quarter, an 18% increase year-over-year from the
Biote Reports First Quarter 2022 Financial Results and Provides Corporate Update Company accelerates expansion and reiterates 2022 guidance IRVING, TX, May 11, 2022 Biote, a high growth, differentiated medical practice-building business within the hormone optimization space, t
Read more →-BTMD
May 4, 2022to this Current Report on Form 8-K. Transaction costs amounted to $16,973,945, consisting of $6,000,000 of underwriting fees, $10,500,000 of deferred underwriting fees, and $473,945 of other offering costs. In addition,
HAYMAKER ACQUISITION CORP. III INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm (PCAOB ID #688 ) 2 Balance Sheet as of March 4, 2021 (As Restated) 3 Notes to Financial Statement (As Restated) 4 REPORT OF INDEPENDENT REGISTERED PUBLI
Read more →-BTMD
Feb 28, 2022THIS PROMISSORY NOTE ( NOTE ) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT ). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN TH
THIS PROMISSORY NOTE ( NOTE ) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT ). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE S
Read more →-BTMD
Dec 14, 2021Andy Heyer: Welcome to the Biote corporate presentation. This is Andy Heyer from Haymaker III, and we re excited you can join us. Biote is a really dynamic consumer healthcare company, and we re really looking forward to
Welcome to the Biote corporate presentation. This is Andy Heyer from Haymaker III, and we re excited you can join us. Biote is a really dynamic consumer healthcare company, and we re really looking forward to telling you about it. The key players are shown here. As many of you k
Read more →-BTMD
Dec 13, 2021Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III Biote is a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization spac
Biote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III IRVING, TX, December 13, 2021 BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space ( Biote ), and Hay
Read more →-BTMD
Apr 22, 2021Haymaker Acquisition Corp. III Announces the Separate Trading of its Class A Common Stock and Redeemable Warrants Commencing
Haymaker Acquisition Corp. III Announces the Separate Trading of its Class A Common Stock and Redeemable Warrants Commencing April 22, 2021 NEW YORK, NY, April 19, 2021 (GLOBE NEWSWIRE) Haymaker Acquisition Corp. III (NASDAQ: HYACU) (the Company ) today announced that, commenci
Read more →-BTMD
Mar 11, 2021to this Current Report on Form 8-K. Transaction costs amounted to $16,973,945, consisting of $6,000,000 of underwriting fees, $10,500,000 of deferred underwriting fees and $473,945 of Initial Public Offering costs. In ad
INDEX TO FINANCIAL STATEMENT Page Report of Independent Registered Public Accounting Firm 2 Balance Sheet 3 Notes to the Balance Sheet 4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Acquisition Corp. III Op
Read more →-BTMD
Mar 1, 2021Haymaker Acquisition Corp. III Announces Pricing of $300 Million Initial Public Offering
Haymaker Acquisition Corp. III Announces Pricing of $300 Million Initial Public Offering NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) Haymaker Acquisition Corp. III (the Company ) today announced the pricing of its initial public offering of 30,000,000 units at a price of $10.00 p
Read more →Competitive Position
How BTMD ranks across every disease it competes inCompetitive Position is a premium feature
See how BTMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial